Compare BDN & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDN | ASMB |
|---|---|---|
| Founded | 1986 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.8M | 553.6M |
| IPO Year | N/A | 2010 |
| Metric | BDN | ASMB |
|---|---|---|
| Price | $3.01 | $35.38 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.00 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 2.5M | 121.8K |
| Earning Date | 10-22-2025 | 11-10-2025 |
| Dividend Yield | ★ 10.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $403,561,000.00 | $37,191,000.00 |
| Revenue This Year | $52.95 | $42.01 |
| Revenue Next Year | $3.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 31.34 | 31.30 |
| 52 Week Low | $3.00 | $7.75 |
| 52 Week High | $5.90 | $39.71 |
| Indicator | BDN | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 26.79 | 56.25 |
| Support Level | $3.28 | $33.28 |
| Resistance Level | $3.39 | $36.00 |
| Average True Range (ATR) | 0.10 | 2.07 |
| MACD | -0.02 | -0.50 |
| Stochastic Oscillator | 3.98 | 37.04 |
Brandywine Realty Trust engaged in the acquisition, development, redevelopment, ownership, management, and operation of a portfolio of office, life science/lab, residential, and mixed-use properties. The company owned and managed properties within five segments. The Philadelphia CBD segment includes properties located in the City of Philadelphia in Pennsylvania. The Pennsylvania Suburbs segment includes properties in Chester, Delaware and Montgomery counties in the Philadelphia suburbs. The Austin, Texas segment includes properties in the City of Austin, Texas. The Metropolitan Washington, D.C. segment includes properties in Northern Virginia, Washington, D.C. and Southern Maryland. The Other segment includes properties in Camden County, New Jersey and New Castle County, Delaware.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.